uniQure N.V. (uniQure) is a gene therapy company. The Company is engaged in developing single treatments with curative results for patients suffering from genetic and other severe diseases. The Company is advancing a focused pipeline of gene therapies that have been developed both internally and through partnerships. The Company's product candidates include AMT-060 for Hemophilia B, AMT-130 for Huntington's disease, S100A1 for congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). uniQure has established clinical proof-of-concept in its lead indication, hemophilia B and has achieved pre-clinical, proof-of-concept in Huntington's disease. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:QURE
- CUSIP: N/A
- Web: www.uniqure.com
- Market Cap: $208.94 million
- Outstanding Shares: 25,443,000
- 50 Day Moving Avg: $5.94
- 200 Day Moving Avg: $5.80
- 52 Week Range: $4.72 - $9.72
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.73
- P/E Growth: 0.00
- Annual Revenue: $24.12 million
- Price / Sales: 8.64
- Book Value: $1.80 per share
- Price / Book: 4.55
- EBIDTA: ($66,070,000.00)
- Net Margins: -223.38%
- Return on Equity: -103.26%
- Return on Assets: -36.63%
- Debt-to-Equity Ratio: 0.39%
- Current Ratio: 6.04%
- Quick Ratio: 6.04%
- Average Volume: 127,652 shs.
- Beta: 0.32
- Short Ratio: 6.36
Frequently Asked Questions for uniQure N.V. (NASDAQ:QURE)
What is uniQure N.V.'s stock symbol?
uniQure N.V. trades on the NASDAQ under the ticker symbol "QURE."
How were uniQure N.V.'s earnings last quarter?
uniQure N.V. (NASDAQ:QURE) released its earnings results on Tuesday, May, 9th. The company reported ($0.80) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.64) by $0.16. The firm earned $3.32 million during the quarter, compared to analyst estimates of $4.20 million. uniQure N.V. had a negative net margin of 223.38% and a negative return on equity of 103.26%. View uniQure N.V.'s Earnings History.
Where is uniQure N.V.'s stock going? Where will uniQure N.V.'s stock price be in 2017?
8 equities research analysts have issued 12 month target prices for uniQure N.V.'s stock. Their predictions range from $8.00 to $27.00. On average, they expect uniQure N.V.'s stock price to reach $16.57 in the next year. View Analyst Ratings for uniQure N.V..
What are analysts saying about uniQure N.V. stock?
Here are some recent quotes from research analysts about uniQure N.V. stock:
- 1. Cowen and Company analysts commented, "QURE reported 1Q17 financials and presented multiple updates at ASGCT recently." (5/24/2017)
- 2. According to Zacks Investment Research, "UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. " (5/17/2017)
Who are some of uniQure N.V.'s key competitors?
Some companies that are related to uniQure N.V. include Adaptimmune Therapeutics PLC (ADAP), Bellicum Pharmaceuticals (BLCM), BioSpecifics Technologies Corp (BSTC), Ra Pharmctl (RARX), BioTime (BTX), Selecta Biosciences (SELB), Corbus Pharmaceuticals Holdings (CRBP), Rigel Pharmaceuticals (RIGL), Edge Therapeutics (EDGE), Merus N.V. (MRUS), Minerva Neurosciences (NERV), GlycoMimetics (GLYC), AVEO Pharmaceuticals (AVEO), DURECT Corporation (DRRX), Ardelyx (ARDX), Oxford BioMedica plc (OXB), Stemline Therapeutics (STML) and Immune Design Corp. (IMDZ).
Who owns uniQure N.V. stock?
How do I buy uniQure N.V. stock?
Shares of uniQure N.V. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is uniQure N.V.'s stock price today?
MarketBeat Community Rating for uniQure N.V. (NASDAQ QURE)MarketBeat's community ratings are surveys of what our community members think about uniQure N.V. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of uniQure N.V. stock can currently be purchased for approximately $8.19.
Consensus Ratings for uniQure N.V. (NASDAQ:QURE) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Hold Ratings, 6 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.75)|
|Consensus Price Target: ||$16.57 (102.34% upside)|
Analysts' Ratings History for uniQure N.V. (NASDAQ:QURE)
(Data available from 7/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|6/30/2017||Oppenheimer Holdings, Inc.||Reiterated Rating||Outperform||$17.00||Low|
|5/24/2017||Cowen and Company||Reiterated Rating||Buy||Medium|
|4/12/2017||Jefferies Group LLC||Reiterated Rating||Hold||$8.00||Low|
|1/30/2017||Chardan Capital||Reiterated Rating||Positive||$12.00||N/A|
|12/2/2016||Leerink Swann||Reiterated Rating||Outperform||N/A|
|12/6/2016||WallachBeth Capital||Lower Price Target||Buy||$27.00 -> $15.00||N/A|
|11/15/2016||Piper Jaffray Companies||Downgrade||Overweight -> Neutral||N/A|
|8/4/2016||HC Wainwright||Initiated Coverage||Buy||$21.00||N/A|
|1/8/2016||Janney Montgomery Scott||Reiterated Rating||Buy||N/A|
|1/8/2016||Roth Capital||Reiterated Rating||Buy||$37.00||N/A|
Earnings History for uniQure N.V. (NASDAQ:QURE)Earnings History by Quarter for uniQure N.V. (NASDAQ QURE)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/9/2017||3/31/2017||($0.64)||($0.80)||$4.20 million||$3.32 million||View||N/A|
|5/31/2016||Q1||($0.82)||($0.93)||$2.94 million||$4.30 million||View||N/A|
|4/4/2016||Q415||($0.60)||($0.58)||$2.78 million||$6.78 million||View||N/A|
|11/30/2015||Q315||($0.64)||($1.14)||$7.76 million||$3.50 million||View||Listen|
|8/27/2015||Q215||($0.56)||($0.98)||$31.18 million||$1.79 million||View||N/A|
|6/11/2015||Q1||($0.82)||($0.69)||$9.50 million||$1.17 million||View||N/A|
|4/6/2015||($0.62)||($0.77)||$1.38 million||$1.61 million||View||N/A|
|12/1/2014||($0.53)||($0.61)||$2.00 million||$1.30 million||View||N/A|
|9/2/2014||Q214||($0.55)||($1.35)||$1.40 million||$1.37 million||View||N/A|
|6/6/2014||($0.45)||($0.52)||$0.84 million||$1.59 million||View||N/A|
Earnings Estimates for uniQure N.V. (NASDAQ:QURE)
2017 EPS Consensus Estimate: ($2.73)
2018 EPS Consensus Estimate: ($2.44)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for uniQure N.V. (NASDAQ:QURE)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for uniQure N.V. (NASDAQ:QURE)
Latest Headlines for uniQure N.V. (NASDAQ:QURE)
uniQure N.V. (QURE) Chart for Sunday, July, 23, 2017